Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy
暂无分享,去创建一个
Y. Shimada | T. Hamaguchi | Y. Horita | T. Nakajima | Y. Yamada | K. Kato | Y. Hirashima
[1] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[4] B. Mounho,et al. Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics , 2005, International journal of toxicology.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[7] E. Ward,et al. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.
[8] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[9] S. Guichard,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0364 CPT-11 converting carboxylesterase and topoisomerase I , 2022 .
[10] A. Kurita,et al. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[11] L. Wienkers,et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[12] J. Armand,et al. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] S. Wadler,et al. A REVIEW OF THE CLINICAL EXPERIENCE WITH IRINOTECAN (CPT‐11) , 1997, American journal of therapeutics.